AIM ImmunoTech (AIMI) AI Stock Analysis

• Market Cap: $5.12M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: -24.35%
• EPS Growth: 61.00%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -8.00
• Shares Outstanding: 764,239
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.50
• Price Target Upside: -77.61% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: $6.50 ▼(-2.99%Downside)

AIM ImmunoTech faces significant financial challenges with declining revenue and persistent losses. Technical indicators suggest weak market momentum, and valuation metrics highlight unprofitability. However, the recent regaining of NYSE compliance is a positive step towards market stability.

Positive Factors

Analyst Rating

The analyst maintains a BUY rating for AIM, seeing large upside opportunities that balance high risks with high growth prospects.

Clinical Trials

Positive data from a Phase 2 study for Ampligen as a therapeutic for patients with post-COVID conditions could boost stock performance.

Negative Factors

Corporate Governance

Dissident stockholders have nominated their own slate of directors for the third consecutive year, indicating potential ongoing governance challenges.

Stock Listing

The company's stock has been delisted from NYSE American and is now trading on Pink Open Market, which might impact investor confidence.

AIM ImmunoTech Business Overview & Revenue Model

Company Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

How the Company Makes Money

AIM ImmunoTech makes money primarily through partnerships, licensing agreements, and grants related to its proprietary drug, Ampligen. The company seeks to monetize its research and development efforts by collaborating with other pharmaceutical companies, which may include receiving upfront payments, milestone payments, and royalties based on product sales. Additionally, AIM may receive revenue from government and private research grants that support the development of its therapies. The company's revenue streams are significantly influenced by the progress of clinical trials and regulatory approvals of its key products.

AIM ImmunoTech Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

AIM ImmunoTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.47B	-0.04	-63.86%	2.34%	16.17%	0.25%
AIMI	45 Neutral	$5.12M	―	-3138.91%	―	-24.35%	61.00%
APLM	42 Neutral	$6.62M	―	-233.67%	―	―	-1786.46%
ACXP	39 Underperform	$12.75M	―	-285.79%	―	―	23.65%
INDP	27 Underperform	$6.79M	―	-259.00%	―	―	11.97%
PMCB	―	$7.69M	1.34	45.44%	―	―	―
OCEA	―	$1.74M	―		―	―	―

AIM ImmunoTech Corporate Events

AIM ImmunoTech Regains NYSE Compliance, Stock Reinstated

On June 11, 2025, AIM ImmunoTech announced that it has regained compliance with the NYSE American’s listing requirements, and its common stock is expected to be reinstated for trading on June 17, 2025, under the ticker symbol ‘AIM’. This follows the company’s recent 1-for-100 reverse stock split, approved by stockholders on April 30, 2025, which aims to increase the per-share market price of its common stock. The reverse split is part of AIM ImmunoTech’s strategy to enhance its market position and comply with exchange regulations, potentially impacting stakeholders by stabilizing its stock’s market presence.

The most recent analyst rating on (AIMI) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIMI Stock Forecast page.